Gain Therapeutics (GANX) News Today $1.69 +0.06 (+3.36%) Closing price 07/3/2025 03:32 PM EasternExtended Trading$1.70 +0.01 (+0.59%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GANX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Gain Therapeutics (NASDAQ:GANX) Receives Buy Rating from HC WainwrightJuly 5 at 2:13 AM | americanbankingnews.comGain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson's Disease With or Without a GBA1 MutationJune 30, 2025 | globenewswire.comScotiabank Sticks to Its Buy Rating for Gain Therapeutics (GANX)June 27, 2025 | theglobeandmail.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of "Buy" by AnalystsJune 15, 2025 | marketbeat.comGain Therapeutics to Participate in Upcoming Investor ConferencesJune 10, 2025 | globenewswire.comGain Therapeutics Announces Oral Presentation at 2nd GBA1 MeetingMay 29, 2025 | globenewswire.comHC Wainwright Issues Optimistic Forecast for GANX EarningsMay 23, 2025 | marketbeat.comGotham Asset Management LLC Sells 176,437 Shares of Gain Therapeutics, Inc. (NASDAQ:GANX)May 23, 2025 | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Average Rating of "Buy" by AnalystsMay 23, 2025 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Earns "Buy" Rating from HC WainwrightMay 21, 2025 | marketbeat.comRoth Capital Predicts Reduced Earnings for Gain TherapeuticsMay 20, 2025 | marketbeat.comGain Therapeutics (GANX) Gets a Buy from ScotiabankMay 16, 2025 | theglobeandmail.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 14, 2025 | finanznachrichten.deGain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate UpdateMay 14, 2025 | globenewswire.comGain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related DisordersMay 13, 2025 | finance.yahoo.comGain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson's Disease and Related DisordersMay 12, 2025 | globenewswire.comGain Therapeutics (GANX) to Release Earnings on TuesdayMay 8, 2025 | marketbeat.comGain Therapeutics to Participate at The Citizens Life Sciences ConferenceMay 1, 2025 | globenewswire.comGain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related DisordersApril 30, 2025 | finance.yahoo.comGain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson's Disease and Related DisordersApril 30, 2025 | globenewswire.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by BrokeragesApril 28, 2025 | marketbeat.comGain Therapeutics (NASDAQ:GANX) Trading Up 1.6% - Here's WhyApril 27, 2025 | marketbeat.comGain Therapeutics presents additional data on study of GT-02287April 11, 2025 | markets.businessinsider.comIs Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 11, 2025 | insidermonkey.comQ1 Earnings Forecast for GANX Issued By Roth CapitalApril 2, 2025 | marketbeat.comGain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Recommendation of "Buy" by AnalystsApril 2, 2025 | marketbeat.comGain Therapeutics (GANX) Receives a Buy from Roth MKMMarch 31, 2025 | markets.businessinsider.comGain Therapeutics (NASDAQ:GANX) Releases Earnings Results, Beats Estimates By $0.07 EPSMarch 29, 2025 | marketbeat.comChardan Capital Reaffirms "Buy" Rating for Gain Therapeutics (NASDAQ:GANX)March 29, 2025 | marketbeat.comGain Therapeutics, Inc.: Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate UpdateMarch 28, 2025 | finanznachrichten.deScotiabank Keeps Their Buy Rating on Gain Therapeutics (GANX)March 28, 2025 | markets.businessinsider.comGain Therapeutics Announces Poster Presentation at AD/PD 2025March 28, 2025 | globenewswire.comGain Therapeutics reports FY24 EPS (89c), consensus ($1.00)March 27, 2025 | markets.businessinsider.comGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate UpdateMarch 27, 2025 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Given Buy Rating at HC WainwrightMarch 18, 2025 | marketbeat.comGain Therapeutics (GANX) to Release Quarterly Earnings on TuesdayMarch 18, 2025 | marketbeat.comShort Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Decreases By 24.5%March 17, 2025 | marketbeat.comGain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson’s DiseaseMarch 14, 2025 | markets.businessinsider.comGain Therapeutics doses first participant in Phase 1b trial of GT-02287March 14, 2025 | markets.businessinsider.comGain Therapeutics Doses First Participant in Phase 1b Clinical Trial of GT-02287 in Parkinson's DiseaseMarch 14, 2025 | globenewswire.comScotiabank Initiates Coverage of Gain Therapeutics (GANX) with Sector Outperform RecommendationMarch 8, 2025 | msn.comGain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Buy" from AnalystsMarch 8, 2025 | marketbeat.comGain Therapeutics initiated with an Outperform at ScotiabankMarch 7, 2025 | markets.businessinsider.comGain Therapeutics Announces Oral Presentation at AD/PD 2025March 6, 2025 | globenewswire.comGain Therapeutics, Inc.: Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational UpdateFebruary 6, 2025 | finanznachrichten.deGain Therapeutics CEO says 2025 ‘poised to be another pivotal year’February 6, 2025 | markets.businessinsider.comGain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational UpdateFebruary 6, 2025 | globenewswire.comGain Therapeutics (NASDAQ:GANX) Shares Up 10.4% - What's Next?February 6, 2025 | marketbeat.comGain Therapeutics To Participate in Upcoming Investor ConferencesFebruary 5, 2025 | globenewswire.comGain Therapeutics regains compliance with Nasdaq listingJanuary 16, 2025 | msn.com Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address GANX Media Mentions By Week GANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GANX News Sentiment▼0.760.57▲Average Medical News Sentiment GANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GANX Articles This Week▼31▲GANX Articles Average Week Get Gain Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GANX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Aurora Cannabis News Neurogene News biote News Acelyrin News Semper Paratus Acquisition News Canopy Growth News ProQR Therapeutics News Nanobiotix News Y-mAbs Therapeutics News I-Mab News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GANX) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s BIGGEST setup yet.After another undefeated quarter, “Market Wizard” Larry Benedict is sounding the alarm on a $194 trillion mark...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gain Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gain Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
